Search results
Naviter Wealth LLC Sells 3,036 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 7 hours agoNaviter Wealth LLC trimmed its position in Pfizer Inc. (NYSE:PFE – Free Report) by 12.3% in the 4th quarter, according to the company in its most recent disclosure with the ...
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty,...
Invezz· 13 hours agoPfizer Inc. has announced its financial outcomes for the first quarter of 2024, displaying strong...
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
BioPharma Dive via Yahoo Finance· 12 hours agoSales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first...
Pfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
GuruFocus.com via Yahoo Finance· 10 hours agoFull-Year Guidance: Adjusted EPS guidance raised to $2.15 to $2.35, reaffirms revenue guidance of...
Pfizer Stock Rises as Outlook Raised After Earnings Beat
Barrons.com· 13 hours agoPfizer reports first-quarter adjusted earnings of 82 cents a share on revenue of $14.88 billion.Read...
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings - ...
Benzinga· 1 day agoPfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has...
Pfizer reports dip in first quarter profits, yet beats estimates
dpa international via Yahoo Finance· 8 hours agoThe US pharmaceutical giant Pfizer on Wednesday said its earnings for the first quarter had declined...
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Zacks via Yahoo Finance· 2 days agoPfizer (PFE) expects its operational revenues to improve, driven by its in-line products like...
Analyst Report: Pfizer Inc.
Morningstar Research via Yahoo Finance· 7 hours agoPfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types ...
Pfizer plans to be 'very active' in obesity market, but CEO mum on precise R&D plans
FierceBiotech· 6 hours agoPfizer’s 2024 revival tour is off and running, but the Big Pharma remains mum on one critical...
